Human ADME Study of [14C]-AZD1390
← catalyst calendarNCT07643870 · readout in 602 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8estimated
Sites
2
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-30 | estimated | When the study began enrolling |
| Primary completion | 2028-04-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-12 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Malignancies
Intervention
- Drug: AZD1390
Primary outcomes
what the primary-completion date above is the date OFThe mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral dose
measured 6 Weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 and the distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
measured 6 weeks
The distribution of total radioactivity into blood cells after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
measured 6 weeks
Pharmacokinetic(s) of AZD1390 after a single oral dose
measured 6 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed